[A field trial for evaluating the safety of recombinant human interferon alpha-2b for nasal spray].
Identifieur interne : 002393 ( PubMed/Checkpoint ); précédent : 002392; suivant : 002394[A field trial for evaluating the safety of recombinant human interferon alpha-2b for nasal spray].
Auteurs : Qing Chen [République populaire de Chine] ; Li-Lan Zhang ; De-Xian Yu ; Zhi-Ai Yu ; Yi Liu ; Li-Ping Zhang ; Zhi-Feng Li ; Zhao-Jun Duan ; Bin-Hui Wang ; Xue-Jun Wei ; Gui-Fang Hu ; Yu-Qing Liu ; Xin-Wei Chu ; Yan-Hong Han ; Min Wu ; Xiao-Ling Jiang ; Jian-Dong Li ; Ying-Chun Dai ; Jun Nie ; Jun Long ; Li Zhu ; Su-Xia Sun ; Yong-Yu Rui ; Ding-Kang Zhang ; Shou-Yi Yu ; Yun-De HouSource :
- Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology [ 1003-9279 ] ; 2005.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Antiviraux (administration et posologie), Antiviraux (effets indésirables), Antiviraux (usage thérapeutique), Céphalée (), Douleur abdominale (), Femelle, Humains, Interféron alpha (administration et posologie), Interféron alpha (effets indésirables), Interféron alpha (usage thérapeutique), Jeune adulte, Mâle, Protéines recombinantes, Résultat thérapeutique, Sensation vertigineuse (), Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (virologie), Virus du SRAS (), Études de suivi.
- MESH :
- administration et posologie : Antiviraux, Interféron alpha.
- effets indésirables : Antiviraux, Interféron alpha.
- usage thérapeutique : Antiviraux, Interféron alpha.
- virologie : Syndrome respiratoire aigu sévère.
- Adolescent, Adulte, Céphalée, Douleur abdominale, Femelle, Humains, Jeune adulte, Mâle, Protéines recombinantes, Résultat thérapeutique, Sensation vertigineuse, Syndrome respiratoire aigu sévère, Virus du SRAS, Études de suivi.
English descriptors
- KwdEn :
- Abdominal Pain (chemically induced), Adolescent, Adult, Antiviral Agents (administration & dosage), Antiviral Agents (adverse effects), Antiviral Agents (therapeutic use), Dizziness (chemically induced), Female, Follow-Up Studies, Headache (chemically induced), Humans, Interferon alpha-2, Interferon-alpha (administration & dosage), Interferon-alpha (adverse effects), Interferon-alpha (therapeutic use), Male, Recombinant Proteins, SARS Virus (drug effects), Severe Acute Respiratory Syndrome (prevention & control), Severe Acute Respiratory Syndrome (virology), Treatment Outcome, Young Adult.
- MESH :
- chemical , administration & dosage : Antiviral Agents, Interferon-alpha.
- chemical , adverse effects : Antiviral Agents, Interferon-alpha.
- chemically induced : Abdominal Pain, Dizziness, Headache.
- drug effects : SARS Virus.
- prevention & control : Severe Acute Respiratory Syndrome.
- chemical , therapeutic use : Antiviral Agents, Interferon-alpha.
- virology : Severe Acute Respiratory Syndrome.
- Adolescent, Adult, Female, Follow-Up Studies, Humans, Interferon alpha-2, Male, Recombinant Proteins, Treatment Outcome, Young Adult.
Abstract
To evaluate the safety of recombinant human interferon alpha-2b for nasal spray for the prevention of SARS and other upper respiratory viral infections.
PubMed: 16261199
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:16261199Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[A field trial for evaluating the safety of recombinant human interferon alpha-2b for nasal spray].</title><author><name sortKey="Chen, Qing" sort="Chen, Qing" uniqKey="Chen Q" first="Qing" last="Chen">Qing Chen</name><affiliation wicri:level="1"><nlm:affiliation>Department of Epidemiology, Southern Medical University, Guangzhou 510515, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Epidemiology, Southern Medical University, Guangzhou 510515</wicri:regionArea><placeName><settlement type="city">Jiangmen</settlement><region type="province">Guangdong</region></placeName></affiliation></author><author><name sortKey="Zhang, Li Lan" sort="Zhang, Li Lan" uniqKey="Zhang L" first="Li-Lan" last="Zhang">Li-Lan Zhang</name></author><author><name sortKey="Yu, De Xian" sort="Yu, De Xian" uniqKey="Yu D" first="De-Xian" last="Yu">De-Xian Yu</name></author><author><name sortKey="Yu, Zhi Ai" sort="Yu, Zhi Ai" uniqKey="Yu Z" first="Zhi-Ai" last="Yu">Zhi-Ai Yu</name></author><author><name sortKey="Liu, Yi" sort="Liu, Yi" uniqKey="Liu Y" first="Yi" last="Liu">Yi Liu</name></author><author><name sortKey="Zhang, Li Ping" sort="Zhang, Li Ping" uniqKey="Zhang L" first="Li-Ping" last="Zhang">Li-Ping Zhang</name></author><author><name sortKey="Li, Zhi Feng" sort="Li, Zhi Feng" uniqKey="Li Z" first="Zhi-Feng" last="Li">Zhi-Feng Li</name></author><author><name sortKey="Duan, Zhao Jun" sort="Duan, Zhao Jun" uniqKey="Duan Z" first="Zhao-Jun" last="Duan">Zhao-Jun Duan</name></author><author><name sortKey="Wang, Bin Hui" sort="Wang, Bin Hui" uniqKey="Wang B" first="Bin-Hui" last="Wang">Bin-Hui Wang</name></author><author><name sortKey="Wei, Xue Jun" sort="Wei, Xue Jun" uniqKey="Wei X" first="Xue-Jun" last="Wei">Xue-Jun Wei</name></author><author><name sortKey="Hu, Gui Fang" sort="Hu, Gui Fang" uniqKey="Hu G" first="Gui-Fang" last="Hu">Gui-Fang Hu</name></author><author><name sortKey="Liu, Yu Qing" sort="Liu, Yu Qing" uniqKey="Liu Y" first="Yu-Qing" last="Liu">Yu-Qing Liu</name></author><author><name sortKey="Chu, Xin Wei" sort="Chu, Xin Wei" uniqKey="Chu X" first="Xin-Wei" last="Chu">Xin-Wei Chu</name></author><author><name sortKey="Han, Yan Hong" sort="Han, Yan Hong" uniqKey="Han Y" first="Yan-Hong" last="Han">Yan-Hong Han</name></author><author><name sortKey="Wu, Min" sort="Wu, Min" uniqKey="Wu M" first="Min" last="Wu">Min Wu</name></author><author><name sortKey="Jiang, Xiao Ling" sort="Jiang, Xiao Ling" uniqKey="Jiang X" first="Xiao-Ling" last="Jiang">Xiao-Ling Jiang</name></author><author><name sortKey="Li, Jian Dong" sort="Li, Jian Dong" uniqKey="Li J" first="Jian-Dong" last="Li">Jian-Dong Li</name></author><author><name sortKey="Dai, Ying Chun" sort="Dai, Ying Chun" uniqKey="Dai Y" first="Ying-Chun" last="Dai">Ying-Chun Dai</name></author><author><name sortKey="Nie, Jun" sort="Nie, Jun" uniqKey="Nie J" first="Jun" last="Nie">Jun Nie</name></author><author><name sortKey="Long, Jun" sort="Long, Jun" uniqKey="Long J" first="Jun" last="Long">Jun Long</name></author><author><name sortKey="Zhu, Li" sort="Zhu, Li" uniqKey="Zhu L" first="Li" last="Zhu">Li Zhu</name></author><author><name sortKey="Sun, Su Xia" sort="Sun, Su Xia" uniqKey="Sun S" first="Su-Xia" last="Sun">Su-Xia Sun</name></author><author><name sortKey="Rui, Yong Yu" sort="Rui, Yong Yu" uniqKey="Rui Y" first="Yong-Yu" last="Rui">Yong-Yu Rui</name></author><author><name sortKey="Zhang, Ding Kang" sort="Zhang, Ding Kang" uniqKey="Zhang D" first="Ding-Kang" last="Zhang">Ding-Kang Zhang</name></author><author><name sortKey="Yu, Shou Yi" sort="Yu, Shou Yi" uniqKey="Yu S" first="Shou-Yi" last="Yu">Shou-Yi Yu</name></author><author><name sortKey="Hou, Yun De" sort="Hou, Yun De" uniqKey="Hou Y" first="Yun-De" last="Hou">Yun-De Hou</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:16261199</idno><idno type="pmid">16261199</idno><idno type="wicri:Area/PubMed/Corpus">002469</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002469</idno><idno type="wicri:Area/PubMed/Curation">002469</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002469</idno><idno type="wicri:Area/PubMed/Checkpoint">002393</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002393</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[A field trial for evaluating the safety of recombinant human interferon alpha-2b for nasal spray].</title><author><name sortKey="Chen, Qing" sort="Chen, Qing" uniqKey="Chen Q" first="Qing" last="Chen">Qing Chen</name><affiliation wicri:level="1"><nlm:affiliation>Department of Epidemiology, Southern Medical University, Guangzhou 510515, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Epidemiology, Southern Medical University, Guangzhou 510515</wicri:regionArea><placeName><settlement type="city">Jiangmen</settlement><region type="province">Guangdong</region></placeName></affiliation></author><author><name sortKey="Zhang, Li Lan" sort="Zhang, Li Lan" uniqKey="Zhang L" first="Li-Lan" last="Zhang">Li-Lan Zhang</name></author><author><name sortKey="Yu, De Xian" sort="Yu, De Xian" uniqKey="Yu D" first="De-Xian" last="Yu">De-Xian Yu</name></author><author><name sortKey="Yu, Zhi Ai" sort="Yu, Zhi Ai" uniqKey="Yu Z" first="Zhi-Ai" last="Yu">Zhi-Ai Yu</name></author><author><name sortKey="Liu, Yi" sort="Liu, Yi" uniqKey="Liu Y" first="Yi" last="Liu">Yi Liu</name></author><author><name sortKey="Zhang, Li Ping" sort="Zhang, Li Ping" uniqKey="Zhang L" first="Li-Ping" last="Zhang">Li-Ping Zhang</name></author><author><name sortKey="Li, Zhi Feng" sort="Li, Zhi Feng" uniqKey="Li Z" first="Zhi-Feng" last="Li">Zhi-Feng Li</name></author><author><name sortKey="Duan, Zhao Jun" sort="Duan, Zhao Jun" uniqKey="Duan Z" first="Zhao-Jun" last="Duan">Zhao-Jun Duan</name></author><author><name sortKey="Wang, Bin Hui" sort="Wang, Bin Hui" uniqKey="Wang B" first="Bin-Hui" last="Wang">Bin-Hui Wang</name></author><author><name sortKey="Wei, Xue Jun" sort="Wei, Xue Jun" uniqKey="Wei X" first="Xue-Jun" last="Wei">Xue-Jun Wei</name></author><author><name sortKey="Hu, Gui Fang" sort="Hu, Gui Fang" uniqKey="Hu G" first="Gui-Fang" last="Hu">Gui-Fang Hu</name></author><author><name sortKey="Liu, Yu Qing" sort="Liu, Yu Qing" uniqKey="Liu Y" first="Yu-Qing" last="Liu">Yu-Qing Liu</name></author><author><name sortKey="Chu, Xin Wei" sort="Chu, Xin Wei" uniqKey="Chu X" first="Xin-Wei" last="Chu">Xin-Wei Chu</name></author><author><name sortKey="Han, Yan Hong" sort="Han, Yan Hong" uniqKey="Han Y" first="Yan-Hong" last="Han">Yan-Hong Han</name></author><author><name sortKey="Wu, Min" sort="Wu, Min" uniqKey="Wu M" first="Min" last="Wu">Min Wu</name></author><author><name sortKey="Jiang, Xiao Ling" sort="Jiang, Xiao Ling" uniqKey="Jiang X" first="Xiao-Ling" last="Jiang">Xiao-Ling Jiang</name></author><author><name sortKey="Li, Jian Dong" sort="Li, Jian Dong" uniqKey="Li J" first="Jian-Dong" last="Li">Jian-Dong Li</name></author><author><name sortKey="Dai, Ying Chun" sort="Dai, Ying Chun" uniqKey="Dai Y" first="Ying-Chun" last="Dai">Ying-Chun Dai</name></author><author><name sortKey="Nie, Jun" sort="Nie, Jun" uniqKey="Nie J" first="Jun" last="Nie">Jun Nie</name></author><author><name sortKey="Long, Jun" sort="Long, Jun" uniqKey="Long J" first="Jun" last="Long">Jun Long</name></author><author><name sortKey="Zhu, Li" sort="Zhu, Li" uniqKey="Zhu L" first="Li" last="Zhu">Li Zhu</name></author><author><name sortKey="Sun, Su Xia" sort="Sun, Su Xia" uniqKey="Sun S" first="Su-Xia" last="Sun">Su-Xia Sun</name></author><author><name sortKey="Rui, Yong Yu" sort="Rui, Yong Yu" uniqKey="Rui Y" first="Yong-Yu" last="Rui">Yong-Yu Rui</name></author><author><name sortKey="Zhang, Ding Kang" sort="Zhang, Ding Kang" uniqKey="Zhang D" first="Ding-Kang" last="Zhang">Ding-Kang Zhang</name></author><author><name sortKey="Yu, Shou Yi" sort="Yu, Shou Yi" uniqKey="Yu S" first="Shou-Yi" last="Yu">Shou-Yi Yu</name></author><author><name sortKey="Hou, Yun De" sort="Hou, Yun De" uniqKey="Hou Y" first="Yun-De" last="Hou">Yun-De Hou</name></author></analytic><series><title level="j">Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology</title><idno type="ISSN">1003-9279</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Abdominal Pain (chemically induced)</term><term>Adolescent</term><term>Adult</term><term>Antiviral Agents (administration & dosage)</term><term>Antiviral Agents (adverse effects)</term><term>Antiviral Agents (therapeutic use)</term><term>Dizziness (chemically induced)</term><term>Female</term><term>Follow-Up Studies</term><term>Headache (chemically induced)</term><term>Humans</term><term>Interferon alpha-2</term><term>Interferon-alpha (administration & dosage)</term><term>Interferon-alpha (adverse effects)</term><term>Interferon-alpha (therapeutic use)</term><term>Male</term><term>Recombinant Proteins</term><term>SARS Virus (drug effects)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Severe Acute Respiratory Syndrome (virology)</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Antiviraux (administration et posologie)</term><term>Antiviraux (effets indésirables)</term><term>Antiviraux (usage thérapeutique)</term><term>Céphalée ()</term><term>Douleur abdominale ()</term><term>Femelle</term><term>Humains</term><term>Interféron alpha (administration et posologie)</term><term>Interféron alpha (effets indésirables)</term><term>Interféron alpha (usage thérapeutique)</term><term>Jeune adulte</term><term>Mâle</term><term>Protéines recombinantes</term><term>Résultat thérapeutique</term><term>Sensation vertigineuse ()</term><term>Syndrome respiratoire aigu sévère ()</term><term>Syndrome respiratoire aigu sévère (virologie)</term><term>Virus du SRAS ()</term><term>Études de suivi</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiviral Agents</term><term>Interferon-alpha</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiviral Agents</term><term>Interferon-alpha</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antiviraux</term><term>Interféron alpha</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Abdominal Pain</term><term>Dizziness</term><term>Headache</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antiviraux</term><term>Interféron alpha</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Interferon-alpha</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term><term>Interféron alpha</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Interferon alpha-2</term><term>Male</term><term>Recombinant Proteins</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Céphalée</term><term>Douleur abdominale</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Protéines recombinantes</term><term>Résultat thérapeutique</term><term>Sensation vertigineuse</term><term>Syndrome respiratoire aigu sévère</term><term>Virus du SRAS</term><term>Études de suivi</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To evaluate the safety of recombinant human interferon alpha-2b for nasal spray for the prevention of SARS and other upper respiratory viral infections.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16261199</PMID><DateCompleted><Year>2008</Year><Month>12</Month><Day>22</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1003-9279</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>3</Issue><PubDate><Year>2005</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology</Title><ISOAbbreviation>Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi</ISOAbbreviation></Journal><ArticleTitle>[A field trial for evaluating the safety of recombinant human interferon alpha-2b for nasal spray].</ArticleTitle><Pagination><MedlinePgn>211-5</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the safety of recombinant human interferon alpha-2b for nasal spray for the prevention of SARS and other upper respiratory viral infections.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Field epidemiologic evaluation was conducted, the design was randomized and had a synchronously parallel control group. In the study, the drugs were given for five days and all subjects were followed up for ten days.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">During the period of using interferon, body temperature of the experimental group was normal compared to the control group. Experimental group had more influenza-like symptoms than the control group (P < 0.05), such as headache (4.83%-7.09%), dizziness (7.17%-11.63%), lassitude (8.55%-15.06%), muscular soreness (4.43%-7.09%), pharynx dryness (12.10%-17.85%), angina (6.25%-8.72%), abdominal pain (2.30%-5.50%) and diarrhea (2.45%-5.66%). Most of side effects reached their peak with in the first 3 days. Except for pharynx dryness, the incidences of all other side effects declined after completion of the use of the trial drug, and incidences of some symptoms in experimental group were lower than those of the control group. There were no significant differences in the symptoms of cough and expectoration between the experimental group and the control group. The incidence of exanthem in the control group was significantly higher than that in the experimental group. The side effect of bloody nasal mucus was not observed in experimental group, which had been reported by other authors in several volunteer studies.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Using recombinant human interferon alpha-2b for nasal spray could lead to some influenza-like symptoms, however, all those symptoms were mild , reversible, and relieved after completion of the use of the trial drug. No serious side effects were found during the period of following up. The authors conclude that the drug is safe.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Qing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Southern Medical University, Guangzhou 510515, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Li-lan</ForeName><Initials>LL</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>De-xian</ForeName><Initials>DX</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Zhi-ai</ForeName><Initials>ZA</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yi</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Li-ping</ForeName><Initials>LP</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zhi-feng</ForeName><Initials>ZF</Initials></Author><Author ValidYN="Y"><LastName>Duan</LastName><ForeName>Zhao-jun</ForeName><Initials>ZJ</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Bin-hui</ForeName><Initials>BH</Initials></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Xue-jun</ForeName><Initials>XJ</Initials></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Gui-fang</ForeName><Initials>GF</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yu-qing</ForeName><Initials>YQ</Initials></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>Xin-wei</ForeName><Initials>XW</Initials></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Yan-hong</ForeName><Initials>YH</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Min</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Xiao-ling</ForeName><Initials>XL</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jian-dong</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>Dai</LastName><ForeName>Ying-chun</ForeName><Initials>YC</Initials></Author><Author ValidYN="Y"><LastName>Nie</LastName><ForeName>Jun</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Long</LastName><ForeName>Jun</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Li</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Su-xia</ForeName><Initials>SX</Initials></Author><Author ValidYN="Y"><LastName>Rui</LastName><ForeName>Yong-yu</ForeName><Initials>YY</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ding-kang</ForeName><Initials>DK</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Shou-yi</ForeName><Initials>SY</Initials></Author><Author ValidYN="Y"><LastName>Hou</LastName><ForeName>Yun-de</ForeName><Initials>YD</Initials></Author></AuthorList><Language>chi</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi</MedlineTA><NlmUniqueID>9602873</NlmUniqueID><ISSNLinking>1003-9279</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077190">Interferon alpha-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015746" MajorTopicYN="N">Abdominal Pain</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004244" MajorTopicYN="N">Dizziness</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006261" MajorTopicYN="N">Headache</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077190" MajorTopicYN="N">Interferon alpha-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>11</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>12</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>11</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16261199</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>République populaire de Chine</li></country><region><li>Guangdong</li></region><settlement><li>Jiangmen</li></settlement></list><tree><noCountry><name sortKey="Chu, Xin Wei" sort="Chu, Xin Wei" uniqKey="Chu X" first="Xin-Wei" last="Chu">Xin-Wei Chu</name><name sortKey="Dai, Ying Chun" sort="Dai, Ying Chun" uniqKey="Dai Y" first="Ying-Chun" last="Dai">Ying-Chun Dai</name><name sortKey="Duan, Zhao Jun" sort="Duan, Zhao Jun" uniqKey="Duan Z" first="Zhao-Jun" last="Duan">Zhao-Jun Duan</name><name sortKey="Han, Yan Hong" sort="Han, Yan Hong" uniqKey="Han Y" first="Yan-Hong" last="Han">Yan-Hong Han</name><name sortKey="Hou, Yun De" sort="Hou, Yun De" uniqKey="Hou Y" first="Yun-De" last="Hou">Yun-De Hou</name><name sortKey="Hu, Gui Fang" sort="Hu, Gui Fang" uniqKey="Hu G" first="Gui-Fang" last="Hu">Gui-Fang Hu</name><name sortKey="Jiang, Xiao Ling" sort="Jiang, Xiao Ling" uniqKey="Jiang X" first="Xiao-Ling" last="Jiang">Xiao-Ling Jiang</name><name sortKey="Li, Jian Dong" sort="Li, Jian Dong" uniqKey="Li J" first="Jian-Dong" last="Li">Jian-Dong Li</name><name sortKey="Li, Zhi Feng" sort="Li, Zhi Feng" uniqKey="Li Z" first="Zhi-Feng" last="Li">Zhi-Feng Li</name><name sortKey="Liu, Yi" sort="Liu, Yi" uniqKey="Liu Y" first="Yi" last="Liu">Yi Liu</name><name sortKey="Liu, Yu Qing" sort="Liu, Yu Qing" uniqKey="Liu Y" first="Yu-Qing" last="Liu">Yu-Qing Liu</name><name sortKey="Long, Jun" sort="Long, Jun" uniqKey="Long J" first="Jun" last="Long">Jun Long</name><name sortKey="Nie, Jun" sort="Nie, Jun" uniqKey="Nie J" first="Jun" last="Nie">Jun Nie</name><name sortKey="Rui, Yong Yu" sort="Rui, Yong Yu" uniqKey="Rui Y" first="Yong-Yu" last="Rui">Yong-Yu Rui</name><name sortKey="Sun, Su Xia" sort="Sun, Su Xia" uniqKey="Sun S" first="Su-Xia" last="Sun">Su-Xia Sun</name><name sortKey="Wang, Bin Hui" sort="Wang, Bin Hui" uniqKey="Wang B" first="Bin-Hui" last="Wang">Bin-Hui Wang</name><name sortKey="Wei, Xue Jun" sort="Wei, Xue Jun" uniqKey="Wei X" first="Xue-Jun" last="Wei">Xue-Jun Wei</name><name sortKey="Wu, Min" sort="Wu, Min" uniqKey="Wu M" first="Min" last="Wu">Min Wu</name><name sortKey="Yu, De Xian" sort="Yu, De Xian" uniqKey="Yu D" first="De-Xian" last="Yu">De-Xian Yu</name><name sortKey="Yu, Shou Yi" sort="Yu, Shou Yi" uniqKey="Yu S" first="Shou-Yi" last="Yu">Shou-Yi Yu</name><name sortKey="Yu, Zhi Ai" sort="Yu, Zhi Ai" uniqKey="Yu Z" first="Zhi-Ai" last="Yu">Zhi-Ai Yu</name><name sortKey="Zhang, Ding Kang" sort="Zhang, Ding Kang" uniqKey="Zhang D" first="Ding-Kang" last="Zhang">Ding-Kang Zhang</name><name sortKey="Zhang, Li Lan" sort="Zhang, Li Lan" uniqKey="Zhang L" first="Li-Lan" last="Zhang">Li-Lan Zhang</name><name sortKey="Zhang, Li Ping" sort="Zhang, Li Ping" uniqKey="Zhang L" first="Li-Ping" last="Zhang">Li-Ping Zhang</name><name sortKey="Zhu, Li" sort="Zhu, Li" uniqKey="Zhu L" first="Li" last="Zhu">Li Zhu</name></noCountry><country name="République populaire de Chine"><region name="Guangdong"><name sortKey="Chen, Qing" sort="Chen, Qing" uniqKey="Chen Q" first="Qing" last="Chen">Qing Chen</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002393 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002393 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:16261199
|texte= [A field trial for evaluating the safety of recombinant human interferon alpha-2b for nasal spray].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:16261199" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |